187 related articles for article (PubMed ID: 38038795)
1. High-throughput virtual screening of potential inhibitors of GPR52 using docking and biased sampling method for Huntington's disease therapy.
Gupta H; Sahi S
Mol Divers; 2023 Dec; ():. PubMed ID: 38038795
[TBL] [Abstract][Full Text] [Related]
2. Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.
Komatsu H
Front Cell Neurosci; 2021; 15():785703. PubMed ID: 34899193
[TBL] [Abstract][Full Text] [Related]
3. GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes.
Wang C; Zhang YF; Guo S; Zhao Q; Zeng Y; Xie Z; Xie X; Lu B; Hu Y
J Med Chem; 2021 Jan; 64(2):941-957. PubMed ID: 33185430
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.
Komatsu H
J Med Chem; 2021 Jan; 64(2):938-940. PubMed ID: 33443413
[TBL] [Abstract][Full Text] [Related]
5. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
Song H; Li H; Guo S; Pan Y; Fu Y; Zhou Z; Li Z; Wen X; Sun X; He B; Gu H; Zhao Q; Wang C; An P; Luo S; Hu Y; Xie X; Lu B
Brain; 2018 Jun; 141(6):1782-1798. PubMed ID: 29608652
[TBL] [Abstract][Full Text] [Related]
6. A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.
Yao Y; Cui X; Al-Ramahi I; Sun X; Li B; Hou J; Difiglia M; Palacino J; Wu ZY; Ma L; Botas J; Lu B
Elife; 2015 Mar; 4():. PubMed ID: 25738228
[TBL] [Abstract][Full Text] [Related]
7. Orphan GPR52 as an emerging neurotherapeutic target.
Ali S; Wang P; Murphy RE; Allen JA; Zhou J
Drug Discov Today; 2024 Apr; 29(4):103922. PubMed ID: 38387741
[TBL] [Abstract][Full Text] [Related]
8. Targeted Proteomics Combined with Affinity Mass Spectrometry Analysis Reveals Antagonist E7 Acts As an Intracellular Covalent Ligand of Orphan Receptor GPR52.
Ma M; Guo S; Lin X; Li S; Wu Y; Zeng Y; Hu Y; Zhao S; Xu F; Xie X; Shui W
ACS Chem Biol; 2020 Dec; 15(12):3275-3284. PubMed ID: 33258587
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of ligand recognition and self-activation of orphan GPR52.
Lin X; Li M; Wang N; Wu Y; Luo Z; Guo S; Han GW; Li S; Yue Y; Wei X; Xie X; Chen Y; Zhao S; Wu J; Lei M; Xu F
Nature; 2020 Mar; 579(7797):152-157. PubMed ID: 32076264
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput structural dynamics approach for identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy.
Jhinjharia D; Kaushik AC; Sahi S
J Biomol Struct Dyn; 2023 Nov; ():1-21. PubMed ID: 37978906
[TBL] [Abstract][Full Text] [Related]
12. Time-resolved FRET screening identifies small molecular modifiers of mutant Huntingtin conformational inflexibility in patient-derived cells.
Wilbertz JH; Frappier J; Muller S; Gratzer S; Englaro W; Stanek LM; Calamini B
SLAS Discov; 2022 Jun; 27(4):219-228. PubMed ID: 35058188
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
14. Siah-1-interacting protein regulates mutated huntingtin protein aggregation in Huntington's disease models.
Latoszek E; Wiweger M; Ludwiczak J; Dunin-Horkawicz S; Kuznicki J; Czeredys M
Cell Biosci; 2022 Mar; 12(1):34. PubMed ID: 35305696
[TBL] [Abstract][Full Text] [Related]
15. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-modifying enzymes in Huntington's disease.
Sap KA; Geijtenbeek KW; Schipper-Krom S; Guler AT; Reits EA
Front Mol Biosci; 2023; 10():1107323. PubMed ID: 36926679
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Insights into the Self-Activation Pathway and Allosteric Regulation of the Orphan G-Protein-Coupled Receptor GPR52.
Wu Z; Han Z; Tao L; Sun X; Su J; Hu J; Li C
J Chem Inf Model; 2023 Sep; 63(18):5847-5862. PubMed ID: 37651308
[TBL] [Abstract][Full Text] [Related]
19. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
Kumar R; Jade D; Gupta D
J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists.
Murphy RE; Wang P; Ali S; Smith HR; Felsing DE; Chen H; Zhou J; Allen JA
J Med Chem; 2024 Jun; 67(11):9709-9730. PubMed ID: 38788241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
